14 Jun 2024

Tempus

Tempus is an American biotechnology company that provides data and AI services for the healthcare industry. The company collects genomic data from patients, organizes it, and provides insights with the help of machine learning. It has 3.5+ million patient records in its oncology dataset. Tempus' products and services are used in oncology, neurology, life sciences and infectious disease research to provide patients with personalized, targeted therapies.

Tempus offers services both directly to patients and through physicians. The company is headquartered in Chicago, Illinois.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
Share Price
Growth Capital20 Oct, 2022
***
***
***
Series G10 Dec, 2020
***
***
***
Series G13 Mar, 2020
***
***
***
Series F30 May, 2019
***
***
***
Series E29 Aug, 2018
***
***
***
Series D20 Mar, 2018
***
***
***
Series C25 Sep, 2017
***
***
***
Series B17 Apr, 2017
***
***
***
Series B22 Nov, 2016
***
***
***
Series B20 Jun, 2016
***
***
***
Series A21 Sep, 2015
***
***
***

*** - To view the data, please log into your account or create a new one.

News related to Tempus177

Filter by
Sort by
Tempus
Jan 3, 2025 Show on chart

Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions - Tempus

Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of Ca...

Tempushttps://www.tempus.com/news/tempus-now-an-in-network-provider-for-blue-cross-blue-shield-illinois-blue-shield-california-and-more/
Tempus
Dec 13, 2024 Show on chart

Tempus Announces Four Abstracts Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - Tempus

Tempus, a leader in artificial intelligence and precision medicine, today announced four abstracts were accepted for presentation at the 2024 San Antonio Breast Cancer Symposium, which convenes from December 10-13, in San Antonio, Texas. “Presenting our l...

Tempushttps://www.tempus.com/news/pr/tempus-announces-four-abstracts-accepted-for-presentation-at-the-2024-san-antonio-breast-cancer-symposium/
Tempus
Nov 29, 2024 Show on chart

Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference - Tempus

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York...

Tempushttps://www.tempus.com/news/pr/tempus-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference/
Tempus
Nov 15, 2024 Show on chart

Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR® - Tempus

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of...

Tempushttps://www.tempus.com/news/pr/tempus-molecular-profiling-integration-now-available-through-flatirons-oncoemr/
Tempus
Nov 15, 2024 Show on chart

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care - Tempus

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with adva...

Tempushttps://www.tempus.com/news/pr/tempus-publishes-study-highlighting-benefits-of-concurrent-rna-and-dna-sequencing-in-advanced-cancer-care/
Show more (172)

Investors8

New Enterprise AssociatesNew Enterprise Associates
RevolutionRevolution
T. Rowe PriceT. Rowe Price
Baillie GiffordBaillie Gifford
Novo HoldingsNovo Holdings
Franklin TempletonFranklin Templeton
GoogleGoogle
Franklin Templeton InvestmentsFranklin Templeton Investments

Tempus Twitter